InnoCentive CEO On Why Open Innovation is a Necessary Path for Pharma

By • on May 16, 2011

Dwayne Spradlin, CEO of InnoCentive, spoke with R&D Directions about the advantages of using open innovation to accelerate drug development and the need for large pharmaceutical companies to adopt more out-of-the-box research strategies.

Click here to read the full Q&A, which appeared in the April 2011 issue.

For more on this topic, please see Professor Henry Chesbrough’s article “Pharmaceutical Innovation Hits the Wall: How Open Innovation Can Help.”

Image via flickr.

Leave a Comment